Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2URWO)

Drug Name

HLL1-Fab-A3B3 Drug Info

Synonyms

Milatuzumab-Fab-CEA-loaded dendritic cell vaccine (cancer); Milatuzumab-Fab-CEA-loaded dendritic cell vaccine (cancer), Immunomedics

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Investigative	[1]

Cross-matching ID

TTD Drug ID: DM2URWO

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Carcinoembryonic antigen CEA (CD66e)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAR408701	DMXGE3O	Non-small-cell lung cancer	2C25.Y	Phase 3	[2]
Tusamitamab ravtansine	DMMPSA1	Non-small-cell lung cancer	2C25	Phase 3	[3]
IDM-2101	DMABRXY	Colorectal cancer	2B91.Z	Phase 2	[4]
CAP1-6D	DMEYIVW	Pancreatic cancer	2C10	Phase 2	[5]
Pentacea	DMGY5JC	Small-cell lung cancer	2C25.Y	Phase 2	[6]
GI-6207	DM72O6F	Thyroid cancer	2D10	Phase 2	[7]
CeaVac	DM6Z9BV	Colorectal cancer	2B91.Z	Phase 2	[8]
Labetuzumab I-131	DMNO5UE	Colorectal cancer	2B91.Z	Phase 2	[9]
AVX701	DMOPVIQ	Colorectal cancer	2B91.Z	Phase 1/2	[10]
CT84.66	DM6078F	Breast cancer	2C60-2C65	Phase 1/2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carcinoembryonic antigen CEA (CD66e)	TTY6DTE	CEAM5_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2836).
2	ClinicalTrials.gov (NCT02187848) Evaluation of SAR408701 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
3	Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425.
4	Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
5	Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997 Oct 15;57(20):4570-7.
6	Antibody fragments: Hope and hype. MAbs. 2010 Jan-Feb; 2(1): 77-83.
7	Clinical pipeline report, company report or official report of GlobeImmune.
8	Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 1999 Sep;17(9):2889-5.
9	National Cancer Institute Drug Dictionary (drug id 692828).
10	Viral vector-based therapeutic cancer vaccines. Cancer J. 2011 Sep-Oct;17(5):359-71.
11	Technology evaluation: cT84.66, City of Hope. Curr Opin Mol Ther. 2004 Feb;6(1):90-5.